Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | MET | P08581 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3712068 | 0.76 | RAB9A (0.67) | LMNASMN1; SMN2RAB9ANPC1HTT | |
| SCHEMBL17468789 | 0.71 | RAB9A (0.61) | LMNASMN1; SMN2RAB9ANPC1HTT | |
| SCHEMBL17482198 | 0.71 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2RAB9ANPC1HTT | |
| SCHEMBL3661523 | 0.70 | SMN1; SMN2 (0.54) | LMNAPKMSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL23176245 | 0.69 | MET (0.44) | LMNAPKMMETMAPTHSD17B10 | |
| SCHEMBL4138642 | 0.68 | HTT (0.68) | LMNASMN1; SMN2RAB9ANPC1HTT | |
| SCHEMBL17482180 | 0.68 | SMN1; SMN2 (0.57) | LMNASMN1; SMN2RAB9ANPC1HTT | |
| SCHEMBL3780684 | 0.68 | HTT (0.61) | LMNASMN1; SMN2RAB9ANPC1HTT | |
| SCHEMBL7694906 | 0.67 | SMN1; SMN2 (0.70) | LMNASMN1; SMN2RAB9ANPC1HTT | |
| SCHEMBL17482202 | 0.67 | MAPT (0.44) | LMNAPKMSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121449620-A | Triazolo-tetrazine derivative and preparation method and application thereof | 中国科学院过程工程研究所 | 2026-02-03 | — | — | CN | disclosed |
| US-10174064-B2 | Photoactive energetic materials | TRIAD NATIONAL SECURITY, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-9902748-B2 | Photoactive energetic materials | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902748-B2 | Photoactive energetic materials | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160031767-A1 | PHOTOACTIVE ENERGETIC MATERIALS | TRIAD NATIONAL SECURITY, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031767-A1 | PHOTOACTIVE ENERGETIC MATERIALS | TRIAD NATIONAL SECURITY, LLC | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174064-B2 | Photoactive energetic materials | NOX5, TRPM5, MT-ND5 | LMNA 707/4885PKM 576/4885SMN1; SMN2 4635/4885 |
| US-20160031767-A1 | PHOTOACTIVE ENERGETIC MATERIALS | NOX5, TRPM5, MT-ND5 | LMNA 707/4885PKM 576/4885SMN1; SMN2 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.